Vestibular Migraine (Investigational Adjunct)
Investigational adjunct for refractory vestibular migraine; migraine prophylaxis (propranolol, topiramate, amitriptyline) and vestibular rehabilitation remain primary.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for vestibular migraine. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for vestibular migraine is investigational.
- What evidence exists?
- Tier C (investigational). Only anecdotal reports; there are no randomized controlled trials. Evidence-based therapy for vestibular migraine (per Barany Society criteria): acute migraine-specific medications (triptans, ditans, gepants), preventive therapy (beta-blockers propranolol/metoprolol, topiramate, amitriptyline, CGRP monoclonal antibodies erenumab/fremanezumab/galcanezumab/eptinezumab), and vestibular rehabilitation. Trigger identification and lifestyle modification.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Trigger of acute vestibular migraine attack from procedure stress or pain
- Worsening of dizziness or imbalance after the procedure
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Fall risk during or after vertigo attack
- Delay of CGRP monoclonal antibody or other preventive therapy
- Risk of missed structural cause of vertigo (vestibular schwannoma)
- Who should not consider this
- Patients without a confirmed vestibular migraine diagnosis (Barany Society criteria)
- Patients with suspected vestibular schwannoma or other structural cause (MRI required)
- Patients with active acute migraine attack
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Pregnant patients
- Patients who have not tried first-line preventive therapy (propranolol, topiramate, amitriptyline)
- What to ask your clinician
- Has my vestibular migraine diagnosis been confirmed using Barany Society criteria?
- Have I had MRI to rule out vestibular schwannoma or central cause?
- Have I tried first-line preventive medication (propranolol, topiramate, amitriptyline)?
- Am I a candidate for CGRP monoclonal antibodies?
- Have I had vestibular rehabilitation?
- What evidence specifically supports leech therapy for vestibular migraine?
- What is the cost and is it covered by insurance? (typically not covered)
- When to seek urgent care
- Sudden severe headache (worst of life — rule out subarachnoid hemorrhage)
- New weakness, numbness, slurred speech, or vision loss (possible stroke)
- Persistent vertigo with vomiting and inability to walk (possible cerebellar stroke)
- New hearing loss with vertigo (possible labyrinthitis or vestibular schwannoma)
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
What this does NOT mean
- This is NOT FDA-cleared for vestibular migraine.
- Anecdotal reports do NOT establish efficacy versus triptans, gepants, CGRP monoclonal antibodies, or preventive medication.
- It does NOT replace MRI workup for structural causes when indicated.
- It does NOT substitute for vestibular rehabilitation or evidence-based migraine prevention.
- It does NOT distinguish vestibular migraine from stroke, Meniere disease, or vestibular schwannoma.
Safety cross-references
Clinical Profile
- Category
- neurological
- ICD-10
- H81.8X9, G43.A0, G43.A1
- Safety tier
- medium
Evidence Summary
Vestibular migraine is recognized by the Barany Society and IHS as a distinct migraine variant featuring vertigo episodes with migrainous features. Management combines migraine lifestyle and trigger management, acute migraine therapy during attacks, prophylactic medication (propranolol, topiramate, amitriptyline, candesartan), and vestibular rehabilitation. No controlled clinical trial of hirudotherapy for vestibular migraine has been published; any use is investigational and mechanistic only. Proposed mechanisms overlap with migraine prophylaxis discussions (modulation of cervico-cranial venous drainage and trigeminovascular inflammation) but remain speculative.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Bahramsoltani M et al. (2017), n=30
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Vestibular schwannoma or other intracranial lesion not yet excluded
- Untreated Meniere's disease (separate registry entry; different management)
- Recent posterior circulation TIA or stroke
- Discontinuation of migraine prophylaxis
Related Conditions
Cervical Radiculopathy
Off-label use with one RCT (Michalsen 2018) showing significant pain reduction at 7 days in cervical radiculopathy without surgical indication.
Lumbar Radiculopathy (Sciatica)
Off-label use with controlled trial evidence (n=80) showing leg pain and Oswestry score improvement at 4-12 weeks in non-surgical lumbar disc disease.
Migraine
Investigational use with case-series evidence for reduction of migraine frequency and intensity; mechanism plausible via reduction of cervico-cranial venous congestion.
Tension-Type Headache
Investigational use with small case series suggesting frequency reduction in chronic tension headache via reduction of pericranial muscle tension and venous congestion.